Epigenetic plasticity and the hallmarks of cancer

Science

Volumn 357, Issue 6348, 2017, Pages

  Flavahan, William A ^a,b   Gaskell, Elizabeth ^a,b   Bernstein, Bradley E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ACTIVATION ENERGY; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENETICS; METABOLISM; PROTEIN; TUMOR;

CANCER CELL; CARCINOGENESIS; CELL DIVISION; CELL FATE; CELL PLASTICITY; CHROMATIN; DNA METHYLATION; EPIGENETICS; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASM; MOLECULAR CLONING; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; CHEMISTRY; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM;

CARCINOGENESIS; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; ONCOGENES;

EID: 85025612805     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aal2380     Document Type: Review

References (102)

1. R. Margueron, D. Reinberg, Chromatin structure and the inheritance of epigenetic information. Nat. Rev. Genet. 11, 285-296 (2010). doi: 10.1038/nrg2752; pmid: 20300089
2. C. D. Allis, T. Jenuwein, The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487-500 (2016). doi: 10.1038/nrg.2016.59; pmid: 27346641
3. S. B. Baylin, P. A. Jones, A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011). doi: 10.1038/nrc3130; pmid: 21941284
4. M. Esteller, Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008). doi: 10.1056/NEJMra072067; pmid: 18337604
5. A. P. Feinberg, M. A. Koldobskiy, A. Göndör, Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284-299 (2016). doi: 10.1038/nrg.2016.13; pmid: 26972587
6. I. Comet, E. M. Riising, B. Leblanc, K. Helin, Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat. Rev. Cancer 16, 803-810 (2016). doi: 10.1038/nrc.2016.83; pmid: 27658528
7. J. S. You, P. A. Jones, Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 22, 9-20 (2012). doi: 10.1016/j.ccr.2012.06.008; pmid: 22789535
8. H. Shen, P. W. Laird, Interplay between the cancer genome and epigenome. Cell 153, 38-55 (2013). doi: 10.1016/j.cell.2013.03.008; pmid: 23540689
9. M. L. Suvà, N. Riggi, B. E. Bernstein, Epigenetic reprogramming in cancer. Science 339, 1567-1570 (2013). doi: 10.1126/science.1230184; pmid: 23539597
10. J. Kim, S. H. Orkin, Embryonic stem cell-specific signatures in cancer: Insights into genomic regulatory networks and implications for medicine. Genome Med. 3, 75 (2011). doi: 10.1186/gm291; pmid: 22126538
11. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000). doi: 10.1016/S0092-8674(00)81683-9; pmid: 10647931
12. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011). doi: 10.1016/j.cell.2011.02.013; pmid: 21376230
13. J. E. Bradner, D. Hnisz, R. A. Young, Transcriptional addiction in cancer. Cell 168, 629-643 (2017). doi: 10.1016/j.cell.2016.12.013; pmid: 28187285
14. J. R. Dixon, D. U. Gorkin, B. Ren, Chromatin domains: The unit of chromosome organization. Mol. Cell 62, 668-680 (2016). doi: 10.1016/j.molcel.2016.05.018; pmid: 27259200
15. J. Dekker, T. Misteli, Long-range chromatin interactions. Cold Spring Harb. Perspect. Biol. 7, a019356 (2015). doi: 10.1101/cshperspect.a019356; pmid: 26430217
16. J. A. Simon, R. E. Kingston, Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol. Cell 49, 808-824 (2013). doi: 10.1016/j.molcel.2013.02.013; pmid: 23473600
17. R. Margueron et al., Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461, 762-767 (2009). doi: 10.1038/nature08398; pmid: 19767730
18. K. S. Zaret, S. E. Mango, Pioneer transcription factors, chromatin dynamics, and cell fate control. Curr. Opin. Genet. Dev. 37, 76-81 (2016). doi: 10.1016/j.gde.2015.12.003; pmid: 26826681
19. C. H. Waddington, The Strategy of the Genes (George Allen & Unwin, London, 1957).
20. M. Perino, G. J. C. Veenstra, Chromatin control of developmental dynamics and plasticity. Dev. Cell 38, 610-620 (2016). doi: 10.1016/j.devcel.2016.08.004; pmid: 27676434
21. N. Lee, C. Maurange, L. Ringrose, R. Paro, Suppression of Polycomb group proteins by JNK signalling induces transdetermination in Drosophila imaginal discs. Nature 438, 234-237 (2005). doi: 10.1038/nature04120; pmid: 16281037
22. A. Soufi, G. Donahue, K. S. Zaret, Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 151, 994-1004 (2012). doi: 10.1016/j.cell.2012.09.045; pmid: 23159369
23. E. Apostolou, K. Hochedlinger, Chromatin dynamics during cellular reprogramming. Nature 502, 462-471 (2013). doi: 10.1038/nature12749; pmid: 24153299
24. E. Hörmanseder et al., H3K4 methylation-dependent memory of somatic cell identity inhibits reprogramming and development of nuclear transfer embryos. Cell Stem Cell 21, 135-143.e6 (2017). doi: 10.1016/j.stem.2017.03.003; pmid: 28366589
25. T. T. Onder et al., Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598-602 (2012). doi: 10.1038/nature10953; pmid: 22388813
26. B. E. Bernstein et al., A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006). doi: 10.1016/j.cell.2006.02.041; pmid: 16630819
27. A. B. Stergachis et al., Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell 154, 888-903 (2013). doi: 10.1016/j.cell.2013.07.020; pmid: 23953118
28. A. Harikumar, E. Meshorer, Chromatin remodeling and bivalent histone modifications in embryonic stem cells. EMBO Rep. 16, 1609-1619 (2015). doi: 10.15252/embr.201541011; pmid: 26553936
29. C. L. Fisher, A. G. Fisher, Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr. Opin. Genet. Dev. 21, 140-146 (2011). doi: 10.1016/j.gde.2011.01.015; pmid: 21316216
30. A. Piunti, A. Shilatifard, Epigenetic balance of gene expression by Polycomb and COMPASS families. Science 352, aad9780 (2016). doi: 10.1126/science.aad9780; pmid: 27257261
31. K. H. Kim, C. W. M. Roberts, Targeting EZH2 in cancer. Nat. Med. 22, 128-134 (2016). doi: 10.1038/nm.4036; pmid: 26845405
32. C. J. Sneeringer et al., Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 107, 20980-20985 (2010). doi: 10.1073/pnas.1012525107; pmid: 21078963
33. D. B. Yap et al., Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459 (2011). doi: 10.1182/blood-2010-11-321208; pmid: 21190999
34. W. Béguelin et al., EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013). doi: 10.1016/j.ccr.2013.04.011; pmid: 23680150
35. M. T. McCabe et al., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012). doi: 10.1038/nature11606; pmid: 23051747
36. C. Hodges, J. G. Kirkland, G. R. Crabtree, The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb. Perspect. Med. 6, a026930 (2016). doi: 10.1101/cshperspect.a026930; pmid: 27413115
37. J. Zhang et al., Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med. 21, 1190-1198 (2015). doi: 10.1038/nm.3940; pmid: 26366712
38. R. J. H. Ryan et al., Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma. Cancer Discov. 5, 1058-1071 (2015). doi: 10.1158/2159-8290.CD-15-0370; pmid: 26229090
39. P. A. Jones, Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484-492 (2012). doi: 10.1038/nrg3230; pmid: 22641018
40. L. B. Hesson, M. P. Hitchins, R. L. Ward, Epimutations and cancer predisposition: Importance and mechanisms. Curr. Opin. Genet. Dev. 20, 290-298 (2010). doi: 10.1016/j.gde.2010.02.005; pmid: 20359882
41. M. L. Leibowitz, C.-Z. Zhang, D. Pellman, Chromothripsis: A new mechanism for rapid karyotype evolution. Annu. Rev. Genet. 49, 183-211 (2015). doi: 10.1146/annurev-genet- 120213-092228; pmid: 26442848
42. A. Davis, R. Gao, N. Navin, Tumor evolution: Linear, branching, neutral or punctuated? Biochim. Biophys. Acta 1867, 151-161 (2017). doi: 10.1016/j.bbcan.2017.01.003; pmid: 28110020
43. A. Brock, H. Chang, S. Huang, Non-genetic heterogeneity-a mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 10, 336-342 (2009). doi: 10.1038/nrg2556; pmid: 19337290
44. L. I. Shlush et al., Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014). doi: 10.1038/nature13038; pmid: 24522528
45. D. W. Parsons et al., An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008). doi: 10.1126/science.1164382; pmid: 18772396
46. H. Yan et al., IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009). doi: 10.1056/NEJMoa0808710; pmid: 19228619
47. R. A. Cairns, T. W. Mak, Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discov. 3, 730-741 (2013). doi: 10.1158/2159-8290. CD-13-0083; pmid: 23796461
48. W. A. Flavahan et al., Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110-114 (2016). doi: 10.1038/nature16490; pmid: 26700815
49. E. P. Nora et al., Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature 485, 381-385 (2012). doi: 10.1038/nature11049; pmid: 22495304
50. D. Hnisz et al., Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351, 1454-1458 (2016). doi: 10.1126/science.aad9024; pmid: 26940867
51. R. Katainen et al., CTCF/cohesin-binding sites are frequently mutated in cancer. Nat. Genet. 47, 818-821 (2015). doi: 10.1038/ng.3335; pmid: 26053496
52. G. N. Filippova et al., Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNAbinding specificity. Cancer Res. 62, 48-52 (2002). pmid: 11782357
53. A. Kon et al., Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 45, 1232-1237 (2013). doi: 10.1038/ng.2731; pmid: 23955599
54. W. J. Gibson et al., The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848-855 (2016). doi: 10.1038/ng.3602; pmid: 27348297
55. A. D. Marshall et al., CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. Oncogene 10.1038/onc.2017.25 (2017). doi: 10.1038/onc.2017.25; pmid: 28319062
56. C. J. Kemp et al., CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep. 7, 1020-1029 (2014). doi: 10.1016/j.celrep.2014.04.004; pmid: 24794443
57. J. Schwartzentruber et al., Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012). doi: 10.1038/nature10833; pmid: 22286061
58. P. W. Lewis et al., Inhibition of PRC2 activity by a gain-offunction H3 mutation found in pediatric glioblastoma. Science 340, 857-861 (2013). doi: 10.1126/science.1232245; pmid: 23539183
59. S. Bender et al., Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660-672 (2013). doi: 10.1016/j.ccr.2013.10.006; pmid: 24183680
60. G. Wu et al., Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251-253 (2012). doi: 10.1038/ng.1102; pmid: 22286216
61. J. C. Black, C. Van Rechem, J. R. Whetstine, Histone lysine methylation dynamics: Establishment, regulation, and biological impact. Mol. Cell 48, 491-507 (2012). doi: 10.1016/j.molcel.2012.11.006; pmid: 23200123
62. K. Ragunathan, G. Jih, D. Moazed, Epigenetic inheritance uncoupled from sequence-specific recruitment. Science 348, 1258699 (2015). doi: 10.1126/science.1258699; pmid: 25831549
63. P. N. C. B. Audergon et al., Restricted epigenetic inheritance of H3K9 methylation. Science 348, 132-135 (2015). doi: 10.1126/science.1260638; pmid: 25838386
64. S. V. Sharma et al., A chromatin-mediated reversible drugtolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010). doi: 10.1016/j.cell.2010.02.027; pmid: 20371346
65. A. Roesch et al., Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811-825 (2013). doi: 10.1016/j.ccr.2013.05.003; pmid: 23764003
66. B. B. Liau et al., Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233-246.e7 (2017). doi: 10.1016/j.stem.2016.11.003; pmid: 27989769
67. J. C. Black et al., Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev. 29, 1018-1031 (2015). doi: 10.1101/gad.259796.115; pmid: 25995187
68. L. Yang et al., DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias. Cancer Cell 29, 922-934 (2016). doi: 10.1016/j.ccell.2016.05.003; pmid: 27300438
69. R. Lu et al., Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development. Cancer Cell 30, 92-107 (2016). doi: 10.1016/j.ccell.2016.05.008; pmid: 27344947
70. D. A. Landau et al., Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26, 813-825 (2014). doi: 10.1016/j.ccell.2014.10.012; pmid: 25490447
71. K. D. Hansen et al., Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768-775 (2011). doi: 10.1038/ng.865; pmid: 21706001
72. J. Bayliss et al., Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci. Transl. Med. 8, 366ra161 (2016). doi: 10.1101/gad.261982.115; pmid: 26109046
73. S. C. Mack et al., Epigenomic alterations define lethal CIMPpositive ependymomas of infancy. Nature 506, 445-450 (2014). doi: 10.1038/nature13108; pmid: 24553142
74. U. Sharma, O. J. Rando, Metabolic inputs into the epigenome. Cell Metab. 25, 544-558 (2017). doi: 10.1016/j.cmet.2017.02.003; pmid: 28273477
75. R. A. Waterland, R. L. Jirtle, Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 23, 5293-5300 (2003). doi: 10.1128/MCB.23.15.5293-5300.2003; pmid: 12861015
76. T. A. Hore et al., Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naïve pluripotency by complementary mechanisms. Proc. Natl. Acad. Sci. U.S.A. 113, 12202-12207 (2016). doi: 10.1073/pnas.1608679113; pmid: 27729528
77. N. Shyh-Chang et al., Influence of threonine metabolism on Sadenosylmethionine and histone methylation. Science 339, 222-226 (2013). doi: 10.1126/science.1226603; pmid: 23118012
78. B. W. Carey, L. W. S. Finley, J. R. Cross, C. D. Allis, C. B. Thompson, Intracellular a-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413-416 (2015). doi: 10.1038/nature13981; pmid: 25487152
79. Q. Yang et al., AMPK/a-ketoglutarate axis dynamically mediates DNA demethylation in the Prdm16 promoter and brown adipogenesis. Cell Metab. 24, 542-554 (2016). doi: 10.1016/j.cmet.2016.08.010; pmid: 27641099
80. L. N. Booth, A. Brunet, The aging epigenome. Mol. Cell 62, 728-744 (2016). doi: 10.1016/j.molcel.2016.05.013; pmid: 27259204
81. P. Sen, P. P. Shah, R. Nativio, S. L. Berger, Epigenetic mechanisms of longevity and aging. Cell 166, 822-839 (2016). doi: 10.1016/j.cell.2016.07.050; pmid: 27518561
82. C. P. Martinez-Jimenez et al., Aging increases cell-to-cell transcriptional variability upon immune stimulation. Science 355, 1433-1436 (2017). doi: 10.1126/science.aah4115; pmid: 28360329
83. K. Curtin, M. L. Slattery, W. S. Samowitz, CpG island methylation in colorectal cancer: Past, present and future. Pathol. Res. Int. 2011, 902674-902678 (2011). doi: 10.4061/2011/902674; pmid: 21559209
84. S. J. D. O'Keefe, Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol. 13, 691-706 (2016). doi: 10.1038/nrgastro.2016.165; pmid: 27848961
85. D. R. Donohoe et al., The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell 48, 612-626 (2012). doi: 10.1016/j.molcel.2012.08.033; pmid: 23063526
86. L. Shen et al., MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 97, 1330-1338 (2005). doi: 10.1093/jnci/dji275; pmid: 16174854
87. J. K. Killian et al., Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci. Transl. Med. 6, 268ra177 (2014). doi: 10.1101/gad.261982.115; pmid: 26109046
88. L. Salmena, A. Carracedo, P. P. Pandolfi, Tenets of PTEN tumor suppression. Cell 133, 403-414 (2008). doi: 10.1016/j.cell.2008.04.013; pmid: 18455982
89. B. Thienpont et al., Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537, 63-68 (2016). doi: 10.1038/nature19081; pmid: 27533040
90. R. E. Bell et al., Enhancer methylation dynamics contribute to cancer plasticity and patient mortality. Genome Res. 26, 601-611 (2016). doi: 10.1101/gr.197194.115; pmid: 26907635
91. S. Madar, I. Goldstein, V. Rotter, 'Cancer associated fibroblasts'-more than meets the eye. Trends Mol. Med. 19, 447-453 (2013). doi: 10.1016/j.molmed.2013.05.004; pmid: 23769623
92. W. Timp, A. P. Feinberg, Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13, 497-510 (2013). doi: 10.1038/nrc3486; pmid: 23760024
93. W. L. Tam, R. A. Weinberg, The epigenetics of epithelialmesenchymal plasticity in cancer. Nat. Med. 19, 1438-1449 (2013). doi: 10.1038/nm.3336; pmid: 24202396
94. C. M. Heaphy et al., Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425-425 (2011). doi: 10.1126/science.1207313; pmid: 21719641
95. J. D. Lathia, S. C. Mack, E. E. Mulkearns-Hubert, C. L. L. Valentim, J. N. Rich, Cancer stem cells in glioblastoma. Genes Dev. 29, 1203-1217 (2015). doi: 10.1101/gad.261982.115; pmid: 26109046
96. C. L. Cowey, W. K. Rathmell, VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Curr. Oncol. Rep. 11, 94-101 (2009). doi: 10.1007/s11912-009-0015-5; pmid: 19216840
97. S. Inoue et al., Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 30, 337-348 (2016). doi: 10.1016/j.ccell.2016.05.018; pmid: 27424808
98. O. A. Guryanova et al., DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat. Med. 22, 1488-1495 (2016). doi: 10.1038/nm.4210; pmid: 27841873
99. M. Tessema et al., Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29, 5159-5170 (2010). doi: 10.1038/onc.2010.255; pmid: 20562917
100. A. Elias et al., Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin. Cancer Res. 15, 5457-5465 (2009). doi: 10.1158/1078-0432.CCR-09-1125; pmid: 19706813
101. H. Easwaran, H.-C. Tsai, S. B. Baylin, Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716-727 (2014). doi: 10.1016/j.molcel.2014.05.015; pmid: 24905005
102. T. Mazor, A. Pankov, J. S. Song, J. F. Costello, Intratumoral heterogeneity of the epigenome. Cancer Cell 29, 440-451 (2016). doi: 10.1016/j.ccell.2016.03.009; pmid: 27070699